Stock Picks by Stockchase
WATCH LIST

Join 31,265 investors that already signed up
for the daily top picks

MAKING IT EASIER FOR YOU TO PICK STOCKS

The Daily Top Picks by Stockchase delivers stock market expert opinions and stock ideas to your inbox each day.

The Trillion Dollar Company : 5 Expert Opinions on Apple

On August 2, 2018, Apple stock price hitting the $207.5 mark to become the world’s first trillion dollar company. The critic might say – Apple is not the first trillion dollar company. It was PetroChina in 2007. But there are two issue here. Only 2% of the PetroChina was floated in the initial public offer, and second it was on “China’s” Shanghai Stock Exchange. There is a common factor among these two biggest companies. It is “Warren Buffett”. He made an investment in both the companies. Apple stock price jumped on the back of strong earnings results provided on July 31th. Apple provided its third quarter numbers for FY2018. It reported the Earnings Per Share of $2.34 which was above $0.16 above consensus expectations. The Company reported Revenue of $53.3 Billion (+17.4% yoy) which was above $870 Million above consensus expectation. Below are the Top 5 Expert Opinions we found on Stockchase on the Apple Stock…. As of August 15th 2018, Apple had a 18.97 P/E Ratio. In comparison, Amazon has a 149.89 P/E ratio. While the market thinks Amazon will continue to grow faster than Apple, AAPL’s stock might still have some room to grow.

Read more...

Pharma Index going Upwards — Top 3 Drug Manufacturers You Should Consider

2018: Volatile year for drug manufacturers 2018 remains the volatile year for the drug manufacturers. The recent steep rise in US Pharma companies has pushed the overall Pharma index upwards. Upon May 11, 2018 announcement of President Donald J. Trump’s Blueprint To Lower Drug Prices  the pharmaceutical sector took a sigh of relief. The major point which everyone was fearful of were not included in the statement. Trump administration’s intervention, Competition from Generic and “Me-too” drugs were affecting the demands for Branded and Proprietary drugs. Overall this sector remain subdued since beginning of the year up till recently. The proposal excluded the recommendations like – allowing the government to negotiate drug prices directly with manufacturers or importing lower-cost prescription drugs from abroad, and others. Pharma ETF as a benchmark Looking at SPDR Pharma ETF (XPH-N) could be a good benchmark. It has been up more than 10% since last three months. The fund seeks to invest in stocks of companies operating across the pharmaceuticals sector. It invests in stocks of companies across all market capitalizations, with a market capitalization above $500 Million. US Pharma companies has increased the prices in recent periods. This applies to both branded and the old generics drugs. XPH-N SPDR Pharma ETF Based […]

Read more...